Table 2.
Association between anticancer treatment given last 30 days of life and adverse events contributing to death
| Variables | AE contributing to death | OR | 95% CI | P value |
|---|---|---|---|---|
| Treatment last 30 daysa | 32.9% | 2.26 | 1.211–4.216 | 0.01 |
| No treatment last 30 days | 17.8% | |||
| Treatment last 30 daysb | 1.85 | 1.014–3.359 | 0.045 | |
| Age | 0.97 | 0.938–0.995 | 0.021 | |
| Length of stay | 0.98 | 0.984–0.962 | 0.184 | |
| Gender | 1.84 | 0.935–3.623 | 0.047 | |
| Type cancer | 0.145 | |||
| Gastrointestinal | 0.98 | 0.370–2.599 | 0.968 | |
| Respiratory | 0.68 | 0.181–2.516 | 0.559 | |
| Breast and gynaecology | 0.37 | 0.130–1.027 | 0.056 | |
| Urinary | 0.35 | 0.132–0.934 | 0.036 | |
| Haematological | 0.75 | 0.244–2.280 | 0.607 | |
| Others |
Binary logistic regression analyses presenting aunadjusted and badjusted results